📊 ACHV Key Takeaways
Is Achieve Life Sciences, Inc.. (ACHV) a Good Investment?
Achieve Life Sciences is a pre-revenue or failed-commercialization biotech company burning $6.9M annually in operating cash flow with zero revenue generation. Despite maintaining a strong cash position of $28.1M and zero debt, the company exhibits unsustainable fundamentals with $54.6M in operating losses and negative ROE (-95.2%), indicating operational failure in its diagnostic substances business.
Achieve Life Sciences has no revenue, deeply negative earnings, and substantial operating cash burn, so its current fundamentals depend almost entirely on external financing rather than business self-sufficiency. The balance sheet is relatively clean with strong liquidity and no meaningful debt, but absent commercialization progress or a sharp reduction in burn, financial quality remains weak.
Achieve Life Sciences, Inc.. Key Strengths (ACHV)
- Strong cash position of $28.1M providing runway for operations
- Zero debt burden with clean balance sheet (Debt/Equity: 0.00x)
- Adequate liquidity with Current Ratio of 2.62x reducing bankruptcy risk
- Strong liquidity position with $31.93M in cash and current ratio of 5.14x
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Very low capital expenditure needs keep cash usage focused on core development activities
ACHV Stock Risks: Achieve Life Sciences, Inc.. Investment Risks
- Zero revenue indicating complete lack of commercial success or market traction
- Substantial operating losses of $54.6M with negative cash flow despite cash reserves
- Negative returns metrics (ROE -95.2%, ROA -30.7%) signaling fundamental business failure
- Unsustainable cash burn rate will deplete reserves within ~4 years at current trajectory
- No evidence of revenue generation path or viable product commercialization
- No revenue base, leaving the company fully reliant on capital markets or partnerships
- Large recurring losses with net income of -$39.99M and ROE of -119.0%
- Negative free cash flow of -$31.51M raises runway and dilution risk if funding needs persist
Key Metrics to Watch
- Revenue generation and first commercial sales event
- Quarterly operating cash flow trend and burn rate acceleration/deceleration
- Cash balance trajectory and projected runway to profitability or funding events
- Quarterly operating cash burn relative to cash on hand
- Any transition from zero revenue to sustainable collaboration, milestone, or product revenue
Achieve Life Sciences, Inc.. (ACHV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.62x current ratio provides a solid financial cushion.
ACHV Profit Margin, ROE & Profitability Analysis
ACHV vs Healthcare Sector: How Achieve Life Sciences, Inc.. Compares
How Achieve Life Sciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Achieve Life Sciences, Inc.. Stock Overvalued? ACHV Valuation Analysis 2026
Based on fundamental analysis, Achieve Life Sciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Achieve Life Sciences, Inc.. Balance Sheet: ACHV Debt, Cash & Liquidity
ACHV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Achieve Life Sciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.50 indicates the company is currently unprofitable.
ACHV Revenue Growth, EPS Growth & YoY Performance
Achieve Life Sciences, Inc.. Dividends, Buybacks & Capital Allocation
ACHV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Achieve Life Sciences, Inc.. (CIK: 0000949858)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACHV
What is the AI rating for ACHV?
Achieve Life Sciences, Inc.. (ACHV) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACHV's key strengths?
Claude: Strong cash position of $28.1M providing runway for operations. Zero debt burden with clean balance sheet (Debt/Equity: 0.00x). ChatGPT: Strong liquidity position with $31.93M in cash and current ratio of 5.14x. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in ACHV?
Claude: Zero revenue indicating complete lack of commercial success or market traction. Substantial operating losses of $54.6M with negative cash flow despite cash reserves. ChatGPT: No revenue base, leaving the company fully reliant on capital markets or partnerships. Large recurring losses with net income of -$39.99M and ROE of -119.0%.
What is ACHV's revenue and growth?
Achieve Life Sciences, Inc.. reported revenue of $0.0.
Does ACHV pay dividends?
Achieve Life Sciences, Inc.. does not currently pay dividends.
Where can I find ACHV SEC filings?
Official SEC filings for Achieve Life Sciences, Inc.. (CIK: 0000949858) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACHV's EPS?
Achieve Life Sciences, Inc.. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACHV's fundamental grade?
Based on our AI fundamental analysis in June 2026, Achieve Life Sciences, Inc.. has a C grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACHV stock overvalued or undervalued?
Valuation metrics for ACHV: ROE of -95.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACHV's AI grade for 2026?
Our dual AI analysis gives Achieve Life Sciences, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACHV's free cash flow?
Achieve Life Sciences, Inc..'s operating cash flow is $-6.9M, with capital expenditures of $3.0K.
How does ACHV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -95.2% (avg: 15%), current ratio 2.62 (avg: 2).